clemizole hydrochloride
Phase 3- Indications
- Dravet syndrome, Lennox-Gastaut syndrome
Company intelligence / Profile preview
Bioharmony Therapeutics develops first-in-class lysin-based antimicrobials targeting multidrug-resistant Gram-negative bacterial infections. Its lead program targets Acinetobacter baumannii and other serious hospital-acquired pathogens. The company has partnered with Boehringer Ingelheim to advance its bacteriophage lysin therapeutics. Early-stage results are promising but still preclinical.[5][6]
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Bio Harmony Therapeutic Center.